Treatment switch in Fabry disease- a matter of dose?

Patients with Fabry disease (FD) on reduced dose of agalsidase-beta or after switch to agalsidase-alfa show a decline in chronic kidney disease epidemiology collaboration-based estimated glomerular filtration rate (eGFR) and a worsened plasma lyso-Gb3 decrease. Hence, the most effective dose is still a matter of debate.In this prospective observational study, we assessed end-organ damage and clinical symptoms in 78 patients who had received...